Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference
Edesa Biotech (NASDAQ:EDSA) announced participation in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on March 30, 2023. The event will feature a Fireside Chat with CEO Par Nijhawan, available to registered attendees at around 7:00 am ET. Edesa is a clinical-stage biopharmaceutical company focused on innovative treatments for inflammatory and immune-related diseases. Key developments include the Phase 3 study of monoclonal antibody EB05 for Acute Respiratory Distress Syndrome, and a Phase 2 trial for EB06 targeting vitiligo. For meeting arrangements, participants can contact their H.C. Wainwright representative or Edesa directly at investors@edesabiotech.com.
- None.
- None.
TORONTO, ON / ACCESSWIRE / March 23, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the company will participate in a Fireside Chat and host one-on-one meetings at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on March 30, 2023.
The Fireside Chat discussion between Edesa's Chief Executive Officer Par Nijhawan, MD, and an H.C. Wainwright analyst will be made available on March 30, 2023 at approximately 7:00 am ET to registered attendees. To schedule a meeting with Edesa during the conference, please contact your H.C. Wainwright representative or the company directly at investors@edesabiotech.com.
About Edesa Biotech
Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. The company's most advanced drug candidate is EB05, a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immunity responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial of its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. Sign up for news alerts. Connect with us on Twitter and LinkedIn.
Edesa Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.
CONTACT
Gary Koppenjan
Edesa Biotech, Inc.
(805) 488-2800 ext. 150
investors@edesabiotech.com
SOURCE: Edesa Biotech
View source version on accesswire.com:
https://www.accesswire.com/745332/Edesa-Biotech-to-Participate-in-HC-Wainwright-Autoimmune-Inflammatory-Disease-Conference
FAQ
What is the date of the H.C. Wainwright Autoimmune & Inflammatory Disease Conference for Edesa Biotech?
What will Edesa Biotech showcase at the conference?
Who is the CEO of Edesa Biotech?
What drug is Edesa Biotech evaluating in a Phase 3 study?
What is the focus of Edesa Biotech's drug candidate EB06?
